Insider Selling: Spark Therapeutics, Inc. (ONCE) General Counsel Sells 5,000 Shares of Stock

Spark Therapeutics, Inc. (NASDAQ:ONCE) General Counsel Barge Joseph La sold 5,000 shares of Spark Therapeutics stock in a transaction that occurred on Wednesday, June 7th. The stock was sold at an average price of $55.00, for a total transaction of $275,000.00. Following the transaction, the general counsel now directly owns 9,567 shares in the company, valued at approximately $526,185. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Barge Joseph La also recently made the following trade(s):

  • On Monday, April 3rd, Barge Joseph La sold 5,000 shares of Spark Therapeutics stock. The stock was sold at an average price of $52.73, for a total transaction of $263,650.00.

Shares of Spark Therapeutics, Inc. (NASDAQ ONCE) traded up 5.04% during trading on Friday, reaching $58.51. 729,264 shares of the company were exchanged. The company’s market capitalization is $1.82 billion. Spark Therapeutics, Inc. has a one year low of $35.07 and a one year high of $65.99. The firm’s 50 day moving average price is $55.74 and its 200 day moving average price is $56.40.

Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings results on Tuesday, May 9th. The biotechnology company reported ($1.70) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.36) by $0.34. The firm had revenue of $1.27 million during the quarter, compared to analysts’ expectations of $1.35 million. Spark Therapeutics had a negative return on equity of 44.06% and a negative net margin of 745.48%. Spark Therapeutics’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same period in the previous year, the company earned ($0.95) earnings per share. Equities research analysts forecast that Spark Therapeutics, Inc. will post ($6.90) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Spark Therapeutics (NASDAQ:ONCE)

TRADEMARK VIOLATION NOTICE: “Insider Selling: Spark Therapeutics, Inc. (ONCE) General Counsel Sells 5,000 Shares of Stock” was first posted by Markets Daily and is the sole property of of Markets Daily. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://www.themarketsdaily.com/2017/06/16/spark-therapeutics-inc-once-general-counsel-barge-joseph-la-sells-5000-shares-of-stock-updated.html.

Several research analysts recently weighed in on the stock. ValuEngine lowered shares of Spark Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 20th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $94.00 price target on shares of Spark Therapeutics in a research note on Thursday, February 23rd. Jefferies Group LLC set a $59.00 price target on shares of Spark Therapeutics and gave the company a “hold” rating in a research note on Wednesday, February 22nd. Stifel Nicolaus lifted their price target on shares of Spark Therapeutics from $73.00 to $76.00 and gave the company a “buy” rating in a research note on Thursday, February 23rd. Finally, Wedbush reaffirmed an “underperform” rating and issued a $28.00 price target on shares of Spark Therapeutics in a research note on Wednesday, February 22nd. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $68.31.

A number of large investors have recently modified their holdings of ONCE. BlackRock Inc. boosted its stake in shares of Spark Therapeutics by 11,332.0% in the first quarter. BlackRock Inc. now owns 1,840,214 shares of the biotechnology company’s stock valued at $98,158,000 after buying an additional 1,824,117 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Spark Therapeutics by 119.5% in the first quarter. Wellington Management Group LLP now owns 808,782 shares of the biotechnology company’s stock valued at $43,140,000 after buying an additional 440,287 shares during the last quarter. Wells Fargo & Company MN boosted its stake in shares of Spark Therapeutics by 131.8% in the first quarter. Wells Fargo & Company MN now owns 522,894 shares of the biotechnology company’s stock valued at $27,891,000 after buying an additional 297,277 shares during the last quarter. Norges Bank purchased a new stake in shares of Spark Therapeutics during the fourth quarter valued at $8,232,000. Finally, JPMorgan Chase & Co. boosted its stake in shares of Spark Therapeutics by 7.8% in the first quarter. JPMorgan Chase & Co. now owns 1,549,093 shares of the biotechnology company’s stock valued at $82,628,000 after buying an additional 112,596 shares during the last quarter. 89.00% of the stock is currently owned by institutional investors.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply